Ogden Christopher 4
4 · CytomX Therapeutics, Inc. · Filed Mar 21, 2024
Insider Transaction Report
Form 4
Ogden Christopher
Chief Financial Officer
Transactions
- Sale
Common Stock
2024-03-19$2.09/sh−2,971$6,196→ 85,686 total
Footnotes (2)
- [F1]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units.
- [F2]Includes 60,310 restricted stock units.